Researchers led by the AIDS Research Institute IrsiCaixa have shown that HIV-infected cells when they generate proteins also create other defective viruses that cause an immune response, detection that identifies new therapeutic targets for the development of HIV vaccine.
The study, published in ‘Journal of Experimental Medicine,’ also shows that in the laboratory, the immune response created is able to block the virus infection cycle.
Research professor and researcher IrsiCaixa Icrea, Christian Brander, has coordinated a research group with members IrsiCaixa Harvard University in Boston, of Microsoft Research and the British Columbia, Canada, with the aim of find new targets. Brander is also currently the scientific coordinator of a research program of HIV vaccine called HIVACAT. (more…)
